Form 4: Boston Scientific EVP Arthur Butcher Reports Stock Transactions
SEC Form 4 Filing
Arthur Butcher, EVP & Group President at Boston Scientific, reports exercising stock options and selling shares under a pre-established 10b5-1 trading plan.
Summary
- Arthur Butcher, an EVP at Boston Scientific, reported transactions involving Boston Scientific common stock on February 26, 2024.
- Butcher exercised stock options to acquire 3,176 shares at $22.71 and 1,009 shares at $17.26.
- He also sold 9,335 shares at $67.07.
- These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.
- Following these transactions, Butcher directly owns 28,937 shares of common stock and indirectly owns 2,542 shares through a 401(k) plan.
- He also holds options to purchase 7,063 shares at $17.26 and 22,236 shares at $22.71.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an executive, with no inherently positive or negative implications. The use of a 10b5-1 plan suggests the transactions were pre-planned.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. The use of a 10b5-1 trading plan suggests that these transactions were pre-planned and not based on any specific non-public information.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across the medical device industry.
- Companies like Medtronic, Abbott, and Stryker also utilize stock options as part of their executive compensation packages.
- The vesting schedules and exercise prices of these options are generally aligned with industry norms to incentivize long-term performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the transactions mitigates any significant concerns.
- There is no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2017-02-22 | First anniversary of stock option grant date for 1,009 shares. |
| 2017-06-01 | First anniversary of stock option grant date for 3,176 shares. |
| 2023-11-22 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-02-26 | Date of stock option exercise and sale transactions. |
| 2024-02-27 | Date of Form 4 filing. |
| 2026-02-22 | Expiration date of stock option for 1,009 shares. |
| 2026-06-01 | Expiration date of stock option for 3,176 shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.